Skip to contentI
Insight Molecular Diagnostics Inc.
I
IMDXInsight Molecular Diagnostics Inc. Q1 2023 · 10-Q
Revenue$297.00K$297.00K−21.8% vs Q1 2022 Net Income$3.03M$3.03MN/M vs Q1 2022 EPS Diluted$0.40$0.40N/M vs Q1 2022 Gross Profit$10,000−96.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Insight Molecular Diagnostics Inc. · CIK 1642380 · Engraved from SEC EDGAR
Operating Cash Flow-$8,300,000N/M Margins · derivedGross margin3.4%−61.6 pt vs Q1 2022
Operating margin1969.7%+2763.6 pt vs Q1 2022
Net margin1021.2%+3729.4 pt vs Q1 2022
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end